News headlines about Sientra (NASDAQ:SIEN) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sientra earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.4717633442017 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Breast Implants Market 2018 Business Strategies: Silimed (Sientra), GC Aesthetics, Allergan and Mentor Worldwide (exclusivereportage.com)
- Zacks: Brokerages Expect Sientra (SIEN) Will Announce Quarterly Sales of $15.30 Million (americanbankingnews.com)
- Sientra, Inc. (SIEN): Stock Have a Latest Story: (mosttradedstocks.com)
- Should Analyst help in decision?: Sientra, Inc. (SIEN) (nasdaqplace.com)
- Is it time to Buy Now? Sientra, Inc. (SIEN) (nysestocks.review)
SIEN has been the subject of several research analyst reports. ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Maxim Group lifted their price target on shares of Sientra from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, April 26th. Stifel Nicolaus upgraded shares of Sientra from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Friday, January 19th. Canaccord Genuity cut their price objective on shares of Sientra from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 14th. Finally, Zacks Investment Research raised shares of Sientra from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 24th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $15.17.
Sientra opened at $17.00 on Friday, Marketbeat Ratings reports. Sientra has a 52 week low of $16.61 and a 52 week high of $16.98. The stock has a market capitalization of $326.83 million, a P/E ratio of -6.03 and a beta of -1.11. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.71 and a current ratio of 1.21.
Sientra (NASDAQ:SIEN) last announced its earnings results on Wednesday, May 9th. The medical instruments supplier reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.15). Sientra had a negative net margin of 164.72% and a negative return on equity of 181.25%. The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $14.49 million. During the same period in the previous year, the firm posted $0.61 EPS. The company’s revenue for the quarter was up 95.2% compared to the same quarter last year. analysts forecast that Sientra will post -2.72 EPS for the current fiscal year.
In other news, Director R Scott Greer purchased 11,111 shares of the company’s stock in a transaction that occurred on Monday, May 7th. The shares were acquired at an average cost of $13.50 per share, with a total value of $149,998.50. Following the transaction, the director now owns 52,657 shares in the company, valued at approximately $710,869.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Jeffrey M. Nugent bought 1,852 shares of the company’s stock in a transaction on Monday, May 7th. The stock was bought at an average cost of $13.50 per share, for a total transaction of $25,002.00. Following the completion of the transaction, the chairman now directly owns 299,851 shares of the company’s stock, valued at $4,047,988.50. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 301,853 shares of company stock valued at $4,075,016. Corporate insiders own 31.00% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.